MedOncol(2013)30:361
DOI10.1007/s12032-012-0361-2
ORIGINAL PAPER
FOLFIRINOX for locally advanced and metastatic pancreatic
cancer: single institution retrospective review of efficacy
and toxicity
Krishna S. Gunturu • Xiaopan Yao • Xiangyu Cong •
Jaykumar R. Thumar • Howard S. Hochster •
Stacey M. Stein • Jill Lacy
Received:29August2012/Accepted:2September2012
(cid:2)SpringerScience+BusinessMediaNewYork2012
Abstract AlthoughFOLFIRINOXsignificantlyincreases the efficacy and tolerability of FOLFIRINOX in LAPC
survivalinmetastaticpancreaticcancer(MPC)comparedto and MPC and suggest that dose attenuations of irinotecan
gemcitabine (Conroy et al. N Engl J Med 364:1817–1825, and bolus fluorouracil improve tolerability without com-
2011),toxicitieshavetemperedenthusiasmforitsuseinfull promisingefficacy.
doses.Toassesstheimpactofdoseattenuationsontoxicity
andefficacy,wereviewedourinstitution’sexperiencewith Keywords Pancreatic cancer (cid:2) FOLFIRINOX (cid:2)
FOLFIRINOX in locally advanced pancreatic cancer Metastatic pancreatic cancer (cid:2)
(LAPC)andMPC.Weperformedaretrospectivereviewof Locally advanced pancreatic cancer (cid:2) Dysarthria
dose,toxicity,andefficacyofFOLFIRINOXinallpatients
with LAPC and MPC treated between June 2010 and July
2011atYale.Toxicitiesinallpatientsandresponserate(RR) Introduction
andsurvivalinpreviouslyuntreatedMPCwerecomparedto
data reported by Conroy. Overall survival (OS) and pro- Pancreatic cancer is the fourth leading cause of cancer-
gression-free survival were estimated by Kaplan–Meier related death in men and women [1]. There were an esti-
method. Thirty-five patients were treated (16 LAPC; 19 mated43,920newcasesand37,390deathsfrompancreatic
MPC).Twenty-ninepatientsreceiveddoseattenuationswith cancerintheUnitedStatesin2012,andthe5-yearsurvival
thefirstcycle.Medianrelativedosesofirinotecanandbolus for all patients with pancreatic adenocarcinoma is\5 %
fluorouracilwerelessthanthosereportedbyConroy(64vs. [2]. The vast majority of patients (80–90 %) present with
81 %and66vs.82 %,respectively).RRwas50 %inLAPC incurable metastatic or locally advanced unresectable dis-
and47 %inMPC,andthelatterdid notdiffersignificantly ease. Gemcitabine has been the standard of care for treat-
from the RR reported by Conroy (p = 0.19). OS at 6 and ment of advanced pancreatic cancer for over a decade
12 months in MPC was comparable to OS reported by based on a randomized trial showing an improvement in
Conroy. Grade 3/4 toxicities were less than reported by the one-year survival with gemcitabine compared to fluo-
Conroy, including fatigue (p = 0.009) and neutropenia rouracil (FU) (18 vs. 2 %, p = 0.0001) [3]. Although well
(p\0.0001).Ninepatientsexperiencedtransientdysarthria tolerated, the efficacy of gemcitabine is marginal, with
during irinotecan administration. Our findings validate reported response rates of less than 10 % and median
survivals of less than 7 months in patients with metastatic
disease. Despite promising phase II trials with gemcita-
K.S.Gunturu(cid:2)J.R.Thumar(cid:2)H.S.Hochster(cid:2)
bine-based combinations in advanced pancreatic cancer,
S.M.Stein(cid:2)J.Lacy(&)
the addition of cytotoxic drugs (e.g., FU, capecitabine,
SectionofMedicalOncology,DepartmentofMedicine,
YaleCancerCenter,YaleSchoolofMedicine,333CedarStreet, oxaliplatin, cisplatin, irinotecan) or targeted agents (bev-
POBox208032,NewHaven,CT06520-8032,USA acizumab,cetuixmab,erlotinib)togemcitabinehasyielded
e-mail:Jill.lacy@yale.edu
no meaningful gains in overall survival in multiple ran-
domized trials comparing gemcitabine doublets to gem-
X.Yao(cid:2)X.Cong
SchoolofPublicHealth,YaleUniversity,NewHaven,CT,USA citabine alone, till recently [4–13].
123
Page2of7 MedOncol(2013)30:361
Conroy et al. [14] first reported impressive efficacy and Treatment
acceptabletolerabilityofthecombinationregimenFOLFIR-
INOX(oxaliplatin85 mg/m2over2 h,followedbyirinotecan Full dose FOLFIRINOX consisted of oxaliplatin 85 mg/m2
180 mg/m2over90 minandleucovorin400 mg/m2over2 h, over 2 h, followed by irinotecan (IRI) 180 mg/m2 over
followed by FU 400 mg/m2 bolus and 2,400 mg/m2 46 h 90 minandleucovorin(LV)400 mg/m2over2 h,followedby
continuous infusion) in a phase II study in 46 patients with FU 400 mg/m2 as a bolus and 2,400 mg/m2 as a 46 h con-
unresectable pancreatic cancer (11 locally advanced, 35 tinuousinfusion.Dosemodificationsweremadeatthetreating
metastatic). In this preliminary study, there were no toxic physician’s discretion. All patients received peg-filgrastim
deaths,andtheconfirmedresponseratewas26 %,including with the first cycle and subsequent cycles in the absence of
4 %completeresponserate,andmedianoverallsurvivalwas severeleukocytosis.Patientsroutinelyreceivedpalonosetron,
10.2 months.Subsequently,FOLFIRINOXwascomparedto aprepitant,anddexamethasoneforemesisprophylaxis.
gemcitabine in a randomizedphase III trial inpatients with
metastaticpancreaticcancer[15].Thisstudyshowedsignifi- Assessment
cant improvements in overall survival (11.1 vs. 6.8 mo),
progression-freesurvival (6.4 vs. 3.3 mo) and responserate Patients were evaluated for toxicities at the start of each
(31.6 vs. 9.4 %) with FOLFIRINOX compared to gemcita- cycle with history, examination, performance status, com-
bine. However, FOLFIRINOX was associated with signifi- plete blood count, and metabolic panel. Response assess-
cantlymoregrade3and4toxicitythangemcitabine(diarrhea, ment imaging was obtained after every 4–6 cycles of
neutropenia,febrileneutropenia,thrombocytopeniaandsen- treatment. All scans were systematically reviewed by the
sory neuropathy). Based on this study, FOLFIRINOX is investigators (KSG, JRT) for response by RECIST.
consideredthemosteffectiveregimenformetastaticpancre-
aticcancer,anditisemergingasthenewstandardofcarein Duration of treatment and follow-up
appropriate patients with a good performance status. How-
ever, given its toxicities, there has been a reluctance to use Treatmentwasdiscontinuedatthediscretionofthetreating
FOLFIRINOXinfulldoses,despitethesignificantincreasein physicianforunacceptabletoxicity,progressionofdisease,
efficacyofthisregimencomparedtogemcitabine. or pursuit of alternative therapies, including surgical
It is unknown whether the administration of attenuated resection or radiotherapy for locally advanced disease.
doses of FOLFIRINOX compromises its efficacy. More- Patients were followed for PFS and OS.
over, there is a paucity of data regarding the efficacy of
FOLFIRINOX in patients with non-metastatic locally Statistics
advanced pancreatic cancer. We conducted a retrospective
review of patients with metastatic or locally advanced ToxicitiesintheentireYalegroupwerecomparedwiththe
unresectable pancreatic cancer treated with FOLFIRINOX toxicitiesintheFOLFIRINOX-treatedgroupasreportedby
at Yale’s Smilow Cancer Center to assess the efficacy and Conroyetal.[15].One-sampleproportiontestwasusedto
the toxicities of this regimen as it is used in an academic compare the proportion of grade 3 and 4 adverse events
practice with routine dose attenuations. (AEs).PatientcharacteristicsandRRoftheYalemetastatic
cohortwerecomparedwiththeFOLFIRINOX-treatedgroup
as reported by Conroy et al. [15]. One-sample Wilcoxon
Methods signedranktestorFisher’sexacttestwasusedtocompare
patientcharacteristics.One-sampleproportiontestwasused
Design to compare the RR in previously untreated metastatic
patients. OS and PFS analyses were performed using Kap-
We conducted a retrospective review of all patients with lan–Meier method. Two patients in the metastatic cohort
locally advanced unresectable and metastatic pancreatic whohadreceivedpriorchemotherapyformetastaticdisease
cancertreatedwithFOLFIRINOXatYale’sSmilowCancer wereexcludedfromRRandsurvivalanalysis.
Center between June 2010 and July 2011. We evaluated
patient characteristics, toxicities, response rate (RR), pro-
gression-freesurvival(PFS),andoverallsurvival(OS)based Results
on review of the patients’ medical records and imaging
studies.ToxicitiesintheentireYalecohort(locallyadvanced Patient characteristics
andmetastaticpatients),andpatientcharacteristicsandRRin
themetastaticcohort,werecomparedtotheFOLFIRINOX- 21Between June 2010 and July 2011, 35 patients with
treatedgroupasreportedbyConroyetal.[15]. advanced pancreatic adenocarcinoma were treated with
123
MedOncol(2013)30:361 Page3of7
FOLFIRINOXattheYaleSmilowCancerCenter,including disease. The RR (CR ? PR) in the entire group (locally
16 with locally advanced unresectable disease and 19 with advancedandmetastatic)was48 %,with 1CRand15PR
metastaticdisease.Thedemographicsanddiseasecharacter- in 33 patients. In patients with metastatic disease, the RR
isticsareshowninTable 1.Comparedtotheseriesreportedby was 47 % and did not differ significantly from the RR of
Conroyetal.[15]inpreviouslyuntreatedpatientswithmet- 32 % reported by Conroy et al. in FOLFIRINOX-treated
astatic disease who received FOLFIRINOX, more patients patients (p = 0.19). In patients with locally advanced dis-
withmetastaticdiseaseinourcohortwerefemale(p = 0.006) ease, the RR was 50 %, and two patients were able to
andhadECOGPSof0(p = 0.003).Inour19patientswith undergo resection after 4 and 6 cycles. One of these
metastaticdisease,2hadreceivedprioradjuvantchemother- patients had a near pathologic complete response with
apy, 1 had received prior neoadjuvant chemoradiotherapy, 2 mm of residual tumor.
and2hadreceivedpriorchemotherapyformetastaticdisease.
Progression-free and overall survival
Dose modifications and supportive care
ThesurvivaldataareshowninTable 3andFig. 1.Forthe
Dose modifications were at the discretion of the treating entirecohortofpatients (locallyadvancedandmetastatic),
physician.Only6of35patientsreceivedfulldosesofeach the median PFS was 16.1 months, and the median OS has
drugofFOLFIRINOXwiththefirstcycle.Intheremaining not been reached.
29 patients, dose attenuations with the first cycle were as In patients with metastatic disease, the median PFS and
follows: IRI was reduced in 27 and omitted in 1, OX was OSwere9.9and11.2 months,respectively.ThePFSinthe
reducedin10,bolusFUwasreducedin9andomittedin7, metastatic cohort at 6 and 12 months was 76 and 35 %,
LV was decreased in 11, infusional FU was reduced in 3. respectively, and the OS at 6 and 12 months was 82 and
The median number of cycles received was 11 (range 50 %, respectively. By comparison, the OS at 6 and
1–28). The median relative doses of each drug (in com- 12 months was 75.9 and 48.4 %, respectively, in the
parison with the median relative doses in FOLFIRINOX- FOLFIRINOX-treatedpatientsasreportedbyConroyetal.
treated patients reported by Conroy et al. [15]) were as [15].
follows: OX 90 % (vs. 78 %), IRI 64 % (vs. 81 %), bolus In patients with locally advanced disease, the median
FU66 %(vs.82 %),andinfusionalFU100 %(vs.82 %). PFS and OS have not been reached. The PFS for locally
34of35patientsreceivedpeg-filgrastimwiththefirstcycle advanced disease at 6 and 12 months was 94 and 77 %,
and subsequent cycles, except in the event of severe leu- respectively, and the OS at 6 and 12 months was 94 and
kocytosis, at the discretion of the treating physician. 83 %, respectively.
Efficacy Adverse events
Response Treatment-related grade 3 and 4 toxicities are summarized
in Table 4. There were no toxic deaths attributable to
Response rates in patients with locally advanced and FOLFIRINOX. The incidence of grade 3 or 4 fatigue (5.7
metastaticdiseaseareshowninTable 2.Twoof19patients vs. 23.6 %, p = 0.009) and neutropenia (11.4 vs. 45.7 %,
withmetastaticdiseasewereexcludedfromtheanalysis,as p\0.0001) was significantly decreased in our cohort
they had received prior chemotherapy for metastatic comparedtotheFOLFIRINOX-treatedpatientsasreported
Table1 Patientdemographics
Characteristic Total Locallyadvanced Metastatic Historicaldata15 pvalue*
andcharacteristics
(n=35) (n=16) (n=19) (n=171)
Age 61(48–77) 60(51–77) 62(48–76) 61(25–76) 0.81?
Male 13(37%) 8(50%) 5(26%) 106(62%) 0.006??
Female 22(63%) 8(50%) 14(74%) 65(38%)
ECOGPS
*ComparisonbetweentheYale
0 24(69%) 10(62%) 14(74%) 64(37%) 0.003??
metastaticgroupandhistorical
controlgroupofFOLFIRINOX- 1 11(31%) 6(37%) 5(26%) 106(62%)
treatedpatientsreportedby Priortherapy 5(14%) 0(0%) 5(26%) 0(0%)
Conroyetal.[15]
Tumorlocation
? One-sampleWilcoxon Head 20(57%) 8(50%) 12(63%) 67(39%) 0.05??
signedranktest
Other 15(43%) 8(50%) 7(37%) 104(61%)
?? Fisher’sexacttest
123
Page4of7 MedOncol(2013)30:361
Table2 Objectiveresponse
Total Locallyadvanced Metastatic Historicaldata15 pvalue*
(n=33) (n=16) (n=17) (n=171)
CR 1(3%) 1(6%) 0(0%) 1(0.6%)
PR 15(45%) 7(44%) 8(47%) 53(31%)
SD 13(39%) 7(44%) 6(35%) 66(39%)
PD 2(6%) 0(0%) 2(12%) 26(15%)
CR?PR 16(48%) 8(50%) 8(47%) 54(32%) 0.19
CR?PR?SD 29(88%) 15(94%) 14(82%) 120(70%) 0.43
*ComparisonbetweentheYalemetastaticgroupandhistoricalcontrolgroupofFOLFIRINOX-treatedpatientsreportedbyConroyetal.[15].
pvaluesarebasedonone-sampleproportiontest
Table3 Survival
Overallsurvival Progression-freesurvival
Median(mos) 6-month 12-month Median(mos) 6-month 12-month
Allpatients(n=33) Notreached 88% 68% 16.1 85% 57%
Metastatic(n=17) 11.2 82% 50% 9.9 76% 35%
Locallyadvanced(n=16) Notreached 94% 83% Notreached 94% 77%
Fig.1 Kaplan–Meiersurvival
estimatesofoverallsurvival
(a)andprogression-free
survival(b)ofpatientswith
locallyadvanced(dottedline)
andmetastatic(solidline)
pancreaticcancer
by Conroy et al. [15]. There was a non-significant trend administration of anticholinergic agents (atropine and/or
toward a lower incidence of febrile neutropenia, anemia, diphenhydramine). The first two patients in whom these
thrombocytopenia, vomiting, diarrhea, and neuropathy symptoms developed were hospitalized for neurological
comparedtotheFOLFIRINOX-treatedpatientsasreported work up to rule out a cerebral vascular event; subsequent
by Conroy et al. [15]. Grade 3 or 4 diarrhea in our patient patients were managed as out-patients in the infusion
population was just 2.9 % compared to 12.7 % in the center. Dose reduction of irinotecan and/or pre-medication
FOLFIRINOX-treatedpatientsasreportedbyConroyetal. with anticholinergics, at the discretion of the treating
[15]. physician, prevented or mitigated the severity of these
In our study, there were nine cases of acute onset of neurologic symptoms in subsequent cycles in all patients.
dysarthria and other neurological symptoms during the
FOLFIRINOX infusion. These symptoms included dysar-
thric speech, facial or perioral paresthesias, leg cramps, Discussion
ataxia, and blepharospasm. In all cases, the onset of these
neurologicalsymptomswastemporallyassociatedwiththe Our single institution retrospective study validates the
irinotecan infusion. The symptoms remitted with inter- efficacy of FOLFIRINOX in unselected patients with
ruption of the irinotecan infusion, and in some cases, locally advanced and metastatic pancreatic cancer. The
recurred with re-challenge. In all cases, the symptoms majority of the patients treated at our institution received
resolved completely without specific intervention other attenuated doses of FOLFIRINOX with the first and sub-
than transient interruption of the irinotcan infusion and/or sequent cycles of treatment, and the median relative doses
123
MedOncol(2013)30:361 Page5of7
Table4 Adverseevents
Grade3/4event Yale(n=35) Historicaldata15 pvalue*
(n=171)
Hematologic
Neutropenia 4(11.4%) 75/164(45.7%) \0.0001
Febrileneutropenia 1(2.9%) 9/166(5.4%) 1.0
Thrombocytopenia 1(2.9%) 15/165(9.1%) 0.37
Anemia 0(0%) 13/166(7.8%) 0.11
Non-hematologic
*ComparisonbetweentheYale
Fatigue 2(5.7%) 39/165(23.6%) 0.009
groupandhistoricalcontrol
groupofFOLFIRINOX-treated Diarrhea 1(2.9%) 21/165(12.7%) 0.12
patientsreportedbyConroy Vomiting 1(2.9%) 24/166(14.5%) 0.05
etal.[15].pvaluesarebasedon
Neuropathy 0(0%) 15/166(9.0%) 0.07
one-sampleproportiontest
of IRI and bolus FU were lower than those reported in the Theoptimumtreatmentoflocallyadvancedunresectable
FOLFIRINOX-treated group reported by Conroy et al. pancreatic cancer remains uncertain. Current therapeutic
[15]. Nonetheless, our findings suggest that the efficacy of options include chemoradiation or chemotherapy alone.
FOLFIRINOX was not compromised by these dose modi- Meta-analyses comparing chemotherapy with chemoradia-
fications. The RR of 47 % in our patients with metastatic tion showed no survival benefit and increased toxicity for
diseasewasnotsignificantlydifferentfromtheRRof32 % chemoradiotherapycomparedtochemotherapy[16–18].The
in the FOLFIRINOX-treated patients as reported by Con- combination of gemcitabine and oxaliplatin was compared
royetal.[15].Moreover,theobservedPFSandOSat6and with gemcitabine alone in locally advanced or metastatic
12 months, as well as the median OS and PFS, in our pancreatic cancer in the GERGOR/GISCAD randomized
patients with metastatic disease were also comparable to trial.DespiteanincreasedRRinlocallyadvanceddiseasewith
the survivals reported by Conroy et al. [15] in the FOLF- gemcitabine/oxaliplatin compared to gemcitabine (27 vs.
IRINOX-treated patients. 14 %),theoverallsurvivalwasidenticalat10.3moinboth
Although FOLFIRINOX is associated with a significant arms[7].InasubsequentrandomizedECOGtrialcomparing
increase in response rate and overall survival in metastatic conventionalgemcitabine,gemcitabinefixed-doserate(FDR)
pancreaticcancercomparedtogemcitabine,thetoxicitiesof infusion,andgemcitabine/oxaliplatininadvancedpancreatic
FOLFIRINOXhavetemperedenthusiasmforitsuseinfull cancer,therewasnodifferenceinRR,PFS,orOSbetweenany
doses in community and academic centers [15]. Our study oftheregimens,andthemediansurvivalwasjust9.2 months
suggests that incorporation of modest dose attenuations of inlocallyadvanceddisease[8].
IRIandbolusFUinthemajorityofpatients,inconjunction AlthoughFOLFIRINOXhassuperiorefficacycompared
withroutineuseofgrowthfactorsupportwiththefirstand to gemcitabine in patients with metastatic pancreatic can-
subsequent cycles, is associated with less toxicity than cer, there are limited data regarding its efficacy and toler-
observedintheFOLFIRINOX-treated patients reportedby ability in locally advanced pancreatic cancer. In the initial
Conroyetal.[15].Weobservedasignificantdecreaseinthe phaseIItrialofFOLFIRINOX,only11patientshadlocally
incidenceofgrade3or4fatigueandneutropenia,andatrend advanced disease, and in these patients, the RR was 27 %
towarddecreasedincidenceoffebrileneutropenia,anemia, and median OS was 15.7 mos [14]. In our cohort of 16
thrombocytopenia, diarrhea, vomiting, and neuropathy in patients with locally advanced pancreatic cancer treated
our cohort compared to the FOLFIRINOX-treated patients with FOLFIRINOX, we observed a response rate of 50 %
reportedbyConroyetal.[15].Theimprovedtolerabilityof and a disease control rate of 94 %, confirming impressive
FOLFIRINOXinourinstitution’scohortofpatientsmaybe efficacyofFOLFIRINOXinlocallyadvanceddisease.The
relatedtothedosemodifications,routineuseofgrowthfactor RR in our cohort of locally advanced pancreatic cancer is
support, or the use of aggressive anti-emetic and anti-diar- higher than that reported for gemcitabine-based regimens
rheal regimens. In addition, a higher percentage of our and is similar to the RR reported by Conroy et al. [15] in
patients had an ECOG PS of 0 compared to the FOLFIRI- FOLFIRINOX-treated patients with metastatic disease.
NOX-treatedpatientsreportedbyConroyetal.[15].Inter- The PFS for locally advanced disease at 6 and 12 months
estingly,57 %ofourpatientshadcarcinomaoftheheadof was 94 and 77 %, respectively, and the OS at 6 and
the pancreas, compared to 39 % of patients reported by 12 month was 94 and 83 %, respectively. Two of our 16
Conroyetal.Although31 %ofourpatientshadbiliarystents patients with locally advanced disease were able to
forobstruction,weobservedonlyonecaseofcholangitis. undergo resection, and one patient had near complete
123
Page6of7 MedOncol(2013)30:361
pathological response. Our findings suggest that the effi- FOLFIRINOX in metastatic pancreatic cancer. In patients
cacy andtolerabilityofFOLFIRINOXinlocally advanced with locally advanced and borderline disease, we need to
pancreaticcancerissimilartoitsefficacyinthemetastatic better define the activity ofFOLFIRINOX and itsrole and
setting and support the use of FOLFIRINOX as initial safety in the neoadjuvant setting.
therapy in patients with locally advanced or borderline
disease. Acknowledgments Thisworkwassupportedbydepartmentalfunds
fromtheYaleSchoolofMedicine.
Wereportninecasesofacuteonsetofdysarthriaandother
neurological symptoms (facial or perioral paresthesias, leg
Conflictofinterest None.
cramps,ataxia,andblepharospasm)duringtheFOLFIRINOX
infusion.Theonsetofthesesymptomswastemporallyasso-
ciatedwiththeirinotecaninfusion.Inallcases,thesymptoms
resolvedcompletelywithoutspecificinterventionotherthan References
transient interruption of the irinotecan infusion and/or
administrationofanticholinergicagents(atropineordiphen- 1. JemalA,SiegelR,XuJ,WardE.Cancerstatistics.CACancerJ
Clin.2010;60(5):277–300.doi:10.3322/caac.20073.
hydramine).In some cases, the symptoms recurredwithre-
2. SiegelR,NaishadhamD,JemalA.Cancerstatistics.CACancerJ
initiation of the irinotecan infusion, but resolved with
Clin.2012;62(1):10–29.doi:10.3322/caac.20138.
administrationofanticholinergicagents.Neurotoxiceffectsof 3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg
irinotecan are uncommon, and only four cases have been ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM,
Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD.
reportedintheliterature[19–22].Themechanismbywhich
Improvementsinsurvivalandclinicalbenefitwithgemcitabineas
CNS toxicity occurs after irinotecan infusion is not well
first-line therapy for patients with advanced pancreas cancer: a
understood.Hareletal.[23]proposedthatirinotecancauses randomizedtrial.JClinOncol.1997;15(6):2403–13.
increasedcholinergicactivitybybindingtotheactivesiteof 4. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG,
Benson AB 3rd. Phase III study of gemcitabine in combination
acetylcholinesterase causing its functional inhibition. Cho-
with fluorouracil versus gemcitabine alone in patients with
linergicreceptorsarefoundmoreinthebrainstemnucleiand
advanced pancreatic carcinoma: Eastern Cooperative Oncology
usingcholinergicagentsresultinasurgeofhypoglossalnerve GroupTrialE2297.JClinOncol.2002;20(15):3270–5.
activity[24,25],whichmightexplainthedysarthriaassoci- 5. HeinemannV,BoeckS,HinkeA,LabiancaR,LouvetC.Meta-
analysis of randomized trials: evaluation of benefit from gem-
atedwithirinotecantoxicity.Thismechanismcouldberelated
citabine-based combination chemotherapy applied in advanced
to cholinergic oversensitivity of the neurons in the hypo-
pancreatic cancer. BMC Cancer. 2008;8:82. doi:10.1186/1471-
glossalnervenucleus.Atropinehasnotbeenshowntoprevent 2407-8-82.
dysarthria, and all the reported cases showed that these 6. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E,
SchullerJ,SalettiP,BauerJ,FigerA,PestalozziB,KohneCH,
symptomswerereversibleandseveritydidnotworsenupon
MingroneW,StemmerSM,TamasK,KornekGV,KoeberleD,
re-challengingwithirinotecan[26].Sinceoxaliplatinisrou-
CinaS,BernhardJ,DietrichD,ScheithauerW.Gemcitabineplus
tinelyadministeredprior to irinotecanin the FOLFIRINOX capecitabine compared with gemcitabine alone in advanced
regimen,wespeculatethatoxaliplatinmayenhancetheneu- pancreaticcancer:arandomized,multicenter,phaseIIItrialofthe
Swiss Group for Clinical Cancer Research and the Central
rotoxiceffectsofirinotecan,therebyincreasingtheincidence
European Cooperative Oncology Group. J Clin Oncol.
ofthisraresideeffectofirinotecan.
2007;25(16):2212–7.doi:10.1200/JCO.2006.09.0886.
7. LouvetC,LabiancaR,HammelP,LledoG,ZampinoMG,Andre
T,ZaniboniA,DucreuxM,AitiniE,TaiebJ,FarouxR,LepereC,
de Gramont A. Gemcitabine in combination with oxaliplatin
Conclusions
comparedwithgemcitabinealoneinlocallyadvancedormetastatic
pancreaticcancer:resultsofaGERCORandGISCADphaseIII
Inthissingleinstitutionretrospectivestudy,theroutineuse trial.JClinOncol.2005;23(15):3509–16.doi:10.1200/JCO.2005.
of modest dose attenuations of FOLFIRINOX, in con- 06.023.
8. PoplinE,FengY,BerlinJ,RothenbergML,HochsterH,MitchellE,
junction with growth factor support, was associated with
AlbertsS,O’DwyerP,HallerD,CatalanoP,CellaD,BensonAB
improvedtolerabilitycomparedtofulldoseFOLFIRINOX
3rd. Phase III, randomized study of gemcitabine and oxaliplatin
asreportedbyConroyetal.Ourfindingssuggestthatthese versusgemcitabine(fixed-doserateinfusion)comparedwithgem-
modest dose attenuations do not reduce the efficacy of citabine (30-min infusion) in patients with pancreatic carcinoma
E6201:atrialoftheEasternCooperativeOncologyGroup.JClin
FOLFIRINOX in metastatic pancreatic cancer patients.
Oncol.2009;27(23):3778–85.doi:10.1200/JCO.2008.20.9007.
Moreover, the efficacy of FOLFIRINOX in locally
9. HeinemannV,QuietzschD,GieselerF,GonnermannM,SchonekasH,
advanced disease was comparable to its efficacy in meta- RostA,NeuhausH,HaagC,ClemensM,HeinrichB,Vehling-Kaiser
static disease. Given the number of patients in our series U,FuchsM,FleckensteinD,GesierichW,UthgenanntD,EinseleH,
HolstegeA,HinkeA,SchalhornA,WilkowskiR.Randomizedphase
and the limitations of a retrospective study, our findings
IIItrialofgemcitabinepluscisplatincomparedwithgemcitabinealone
requirefurthersubstantiation.Prospectivetrialsareneeded
inadvancedpancreaticcancer.JClinOncol.2006;24(24):3946–52.
to validate the efficacy and tolerability of modifications of doi:10.1200/JCO.2005.05.1490.
123
MedOncol(2013)30:361 Page7of7
10. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey 17. MoertelCG,FrytakS,HahnRG,O’ConnellMJ,ReitemeierRJ,
GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. RubinJ,SchuttAJ,WeilandLH,ChildsDS,HolbrookMA,Lavin
Irinotecan plus gemcitabine results in no survival advantage PT,LivstoneE,SpiroH,KnowltonA,KalserM,BarkinJ,Lessner
comparedwithgemcitabinemonotherapyinpatientswithlocally H,Mann-KaplanR,RammingK,DouglasHOJr,ThomasP,Nave
advancedormetastaticpancreaticcancerdespiteincreasedtumor H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM,
response rate. J Clin Oncol. 2004;22(18):3776–83. doi:10.1200/ Zamcheck N, Novak JW. Therapy of locally unresectable pan-
JCO.2004.12.08222/18/3776. creaticcarcinoma:arandomizedcomparisonofhighdose(6,000
11. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, rads) radiation alone, moderate dose radiation (4,000 rads?
HurwitzH,InnocentiF,MulcahyMF,O’ReillyE,WozniakTF, 5-fluorouracil),andhighdoseradiation?5-fluorouracil:theGas-
Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. trointestinalTumorStudyGroup.Cancer.1981;48(8):1705–10.
Gemcitabineplusbevacizumabcomparedwithgemcitabineplus 18. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos
placeboinpatientswithadvancedpancreaticcancer:phaseIIItrial JP, Ghaneh P. Meta-analyses of chemotherapy for locally
of the Cancer and Leukemia Group B (CALGB 80303). J Clin advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;
Oncol.2010;28(22):3617–22.doi:10.1200/JCO.2010.28.1386. 25(18):2607–15.doi:10.1200/JCO.2006.09.2551.
12. PhilipPA,BenedettiJ,CorlessCL,WongR,O’ReillyEM,Flynn 19. De Marco S, Squilloni E, Vigna L, Bertagnolio MF, Sternberg
PJ,RowlandKM,AtkinsJN,MirtschingBC,RivkinSE,Khorana CN. Irinotecan chemotherapy associated with transient dysar-
AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke thria and aphasia. Ann Oncol. 2004;15(7):1147–8. doi:10.1093/
CD.PhaseIIIstudycomparinggemcitabinepluscetuximabversus annonc/mdh27715/7/1147.
gemcitabineinpatientswithadvancedpancreaticadenocarcinoma: 20. Baz DV, Bofill JS, Nogueira JA. Irinotecan-induced dysarthria.
SouthwestOncologyGroup-directedintergrouptrialS0205.JClin JNatlCancerInst.2001;93(18):1419–20.
Oncol.2010;28(22):3605–10.doi:10.1200/JCO.2009.25.7550. 21. Hamberg P, De Jong FA, Brandsma D, Verweij J, Sleijfer S.
13. MooreMJ,GoldsteinD,HammJ,FigerA,HechtJR,GallingerS,Au Irinotecan-induced central nervous system toxicity. Report on
HJ,MurawaP,WaldeD,WolffRA,CamposD,LimR,DingK,Clark two cases and review of the literature. Acta Oncol. 2008;47(5):
G,Voskoglou-NomikosT,PtasynskiM,ParulekarW.Erlotinibplus 974–8.doi:10.1080/02841860701666089.
gemcitabine compared with gemcitabine alone in patients with 22. Sevilla Garcia I, Rueda A, Alba E. Irinotecan-induced central
advancedpancreaticcancer:aphaseIIItrialoftheNationalCancer nervoussystemtoxicity:acasereport.JNatlCancerInst.1999;
InstituteofCanadaClinicalTrialsGroup.JClinOncol.2007;25(15): 91(7):647.
1960–6.doi:10.1200/JCO.2006.07.9525. 23. Harel M, Hyatt JL, Brumshtein B, Morton CL, Yoon KJ,
14. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Wadkins RM, Silman I, Sussman JL, Potter PM. The crystal
Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, structureofthecomplexoftheanticancerprodrug7-ethyl-10-[4-
Deplanque G. Irinotecan plus oxaliplatin and leucovorin-modu- (1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11)
lated fluorouracil in advanced pancreatic cancer—a Groupe with Torpedo californica acetylcholinesterase provides a molec-
Tumeurs Digestives of the Federation Nationale des Centres de ularexplanationforitscholinergicaction.MolPharmacol.2005;
LutteContreleCancerstudy.JClinOncol.2005;23(6):1228–36. 67(6):1874–81.doi:10.1124/mol.104.009944.
doi:10.1200/JCO.2005.06.050. 24. CortesR,ProbstA,PalaciosJM.Quantitativelightmicroscopic
15. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, autoradiographiclocalizationofcholinergicmuscarinicreceptors
Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la inthehumanbrain:brainstem.Neuroscience.1984;12(4):1003–26.
Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, 25. HaxhiuMA,MitraJ,vanLunterenE,BruceEN,CherniackNS.
Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Hypoglossalandphrenicresponsestocholinergicagentsapplied
Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcita- to ventral medullary surface. Am J Physiol. 1984;247(6 Pt 2):
bine for metastatic pancreatic cancer. N Engl J Med. 2011; R939–44.
364(19):1817–25.doi:10.1056/NEJMoa1011923. 26. DresselAJ,vanderMijnJC,AaldersIJ,RinkelRN,vanderVliet
16. HuguetF,GirardN,GuercheCS,HennequinC,MornexF,AzriaD. HJ. Irinotecan-induced dysarthria. Case Rep Oncol. 2012;5(1):
Chemoradiotherapyinthemanagementoflocallyadvancedpan- 47–51.doi:10.1159/000336156.
creaticcarcinoma:aqualitativesystematicreview.JClinOncol.
2009;27(13):2269–77.doi:10.1200/JCO.2008.19.7921.
123
